Category News

EU Approves Subcutaneous Opdivo with Halozyme’s ENHANZE for Multiple Tumors

Halozyme and Bristol Myers Squibb Secure European Commission Approval for Subcutaneous Opdivo Co-Formulated with ENHANZE in Multiple Solid Tumors Halozyme Therapeutics celebrates a significant regulatory milestone as Bristol Myers Squibb gains European Commission approval for a new subcutaneous formulation of…

Read MoreEU Approves Subcutaneous Opdivo with Halozyme’s ENHANZE for Multiple Tumors

CHMP Recommends EU Approval of Imfinzi as First Perioperative Immunotherapy for Bladder Cancer

AstraZeneca’s Imfinzi Gains CHMP Backing as First Perioperative Immunotherapy for Muscle-Invasive Bladder Cancer in the EU AstraZeneca has announced a significant regulatory milestone for its cancer immunotherapy, Imfinzi (durvalumab), with the drug receiving a positive recommendation from the Committee for…

Read MoreCHMP Recommends EU Approval of Imfinzi as First Perioperative Immunotherapy for Bladder Cancer